<DOC>
	<DOC>NCT02990611</DOC>
	<brief_summary>Real-Life Efficacy and Safety of Nivolumab monotherapy or in combination with Ipilimumab in Patients with Advanced (Unresectable or Metastatic) Melanoma</brief_summary>
	<brief_title>Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>â‰¥ 18 years advanced melanoma (Stage III/Stage IV) histologically confirmed diagnosis treatment decision for nivolumab mono or combination therapy already taken signed informed consent current primary diagnosis of a cancer other than advanced melanoma, that requires systemic or other treatment previous treatment with nivolumab current active participation in an interventional clinical trial for treatment of advanced melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>